About the Webconference
The FDA approval of transcatheter aortic valves has elicited unprecedented excitement and promises to alter the paradigm for treatment of valve disease. Yet pursuing this technology comes at a significant cost, including facility renovations and dedicated coordinators.
Operational investments may be even more noteworthy: persistent screening, multidisciplinary heart teams, and long-term follow-up care. This presentation provides structural and operational guidance on developing and optimizing valve centers, including detailed profiles from leading centers.
Presenter: Megan Tooley